Mirum Pharmaceuticals (MIRM) News Today → The #1 Crypto for AI (From Weiss Ratings) (Ad) Free MIRM Stock Alerts $24.75 -0.24 (-0.96%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:14 PM | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Nicholas Investment Partners LPNicholas Investment Partners LP trimmed its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 66.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 398,883 shares of tMay 14 at 7:42 AM | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) PT Lowered to $53.00 at Morgan StanleyMay 13, 2024 | finance.yahoo.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call TranscriptMay 13, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Receives Overweight Rating from Cantor FitzgeraldMay 13, 2024 | americanbankingnews.comHC Wainwright Comments on Mirum Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:MIRM)May 13, 2024 | americanbankingnews.comMirum Pharmaceuticals' (MIRM) "Buy" Rating Reaffirmed at HC WainwrightMay 13, 2024 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Forecasted to Post Q2 2024 Earnings of $0.06 Per ShareMay 10, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net LossMay 10, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) PT Lowered to $53.00Morgan Stanley cut their price target on shares of Mirum Pharmaceuticals from $57.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday.May 10, 2024 | markets.businessinsider.comPositive Outlook for Mirum Pharmaceuticals with Buy Rating Amid Upcoming Catalysts and Robust FinancialsMay 10, 2024 | markets.businessinsider.comMirum Pharmaceuticals: Strong Buy Recommendation Amidst Resilient Performance and Promising Clinical ProspectsMay 9, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Increased to $38.00 by Analysts at CitigroupCitigroup upped their price objective on Mirum Pharmaceuticals from $37.00 to $38.00 and gave the company a "buy" rating in a research report on Thursday.May 9, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) PT Lowered to $66.00 at JMP SecuritiesJMP Securities decreased their target price on Mirum Pharmaceuticals from $72.00 to $66.00 and set a "market outperform" rating on the stock in a research note on Thursday.May 9, 2024 | markets.businessinsider.comBuy Rating for Mirum Pharmaceuticals Amidst Strong Sales and Promising Drug PipelineMay 9, 2024 | finance.yahoo.comQ1 2024 Mirum Pharmaceuticals Inc Earnings CallMay 9, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)Cantor Fitzgerald restated an "overweight" rating and set a $40.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday.May 9, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...May 8, 2024 | finance.yahoo.comMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comMirum Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comMirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFICMay 2, 2024 | marketbeat.comMirum Pharmaceuticals (MIRM) Set to Announce Quarterly Earnings on WednesdayMirum Pharmaceuticals (NASDAQ:MIRM) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | businesswire.comMirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 26, 2024 | investing.comMirum Pharmaceuticals Inc (MIRM)April 25, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week Low at $23.14Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month Low at $23.14April 22, 2024 | seekingalpha.comMirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive ValueApril 21, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Knights of Columbus Asset Advisors LLC raised its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 101.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 116,644 shareApril 18, 2024 | msn.comStifel starts Mirum at buy, cites IBATi drug potentialApril 17, 2024 | msn.comStifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy RecommendationApril 17, 2024 | marketbeat.comStifel Nicolaus Initiates Coverage on Mirum Pharmaceuticals (NASDAQ:MIRM)Stifel Nicolaus assumed coverage on Mirum Pharmaceuticals in a research note on Wednesday. They issued a "buy" rating and a $48.00 price objective on the stock.April 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment BreakthroughsApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial OutlookApril 15, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year Low at $24.17Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year Low at $24.17April 10, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by AnalystsShares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have received a consensus rating of "Buy" from the eight analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy rApril 9, 2024 | marketbeat.comVanguard Group Inc. Acquires 98,685 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Vanguard Group Inc. raised its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,693,343 shares of the company's stock after acquiring an additionaApril 2, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $58.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday.April 2, 2024 | finance.yahoo.comMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeApril 2, 2024 | businesswire.comMirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeMarch 28, 2024 | insidertrades.comEric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMarch 27, 2024 | marketbeat.comEric Bjerkholt Acquires 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CFO Eric Bjerkholt bought 2,000 shares of the company's stock in a transaction dated Wednesday, March 27th. The stock was bought at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the transaction, the chief financial officer now owns 14,000 shares of the company's stock, valued at $347,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.March 26, 2024 | insidertrades.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in StockMarch 26, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Insider Sells SharesMarch 25, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 4,303 SharesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 4,303 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at approximately $748,535.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.March 20, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for Mirum Pharmaceuticals in a research note issued on Monday, March 18th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings perMarch 20, 2024 | investing.comMirum Pharmaceuticals COO sells over $28k in company stockMarch 19, 2024 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at Leerink Partnrs reduced their Q1 2024 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, March 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the cMarch 19, 2024 | insidertrades.comEric Bjerkholt Buys 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMarch 18, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Mirum PharmaceuticalsMarch 18, 2024 | marketbeat.comJMP Securities Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $72.00JMP Securities raised their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. MIRM Media Mentions By Week MIRM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼0.220.54▲Average Medical News Sentiment MIRM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼204▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AbCellera Biologics News Today Enliven Therapeutics News Today Belite Bio News Today MannKind News Today Prothena News Today Verona Pharma News Today Collegium Pharmaceutical News Today Xencor News Today Ironwood Pharmaceuticals News Today Innoviva News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
